Rocket Lab Secures $1.94 B ATM Offering to Fully Fund Iridium Acquisition

RKLB said on Monday that it has completed the at-the-market share sale it announced earlier this year, raising approximately $1.944 billion in gross proceeds through the issuance of 29.3 million shares before commissions and offering expenses. With that raise done, Rocket Lab describes its pending acquisition of IRDM as fully funded. The release did not disclose an average price per share.

Two other pieces of the financing moved at the same time. Iridium entered a change-of-control amendment covering its outstanding $1.775 billion term loans, a balance the company dates to June 30, 2026, which lets Rocket Lab's takeover proceed without tripping a default and puts permanent financing in place against Iridium's free cash flow, with Rocket Lab USA guaranteeing it on an unsecured basis at closing. Rocket Lab separately terminated the $3.6 billion senior secured bridge commitment it had taken out alongside the June 28, 2026 merger agreement, swapping expensive standby debt for equity it has already sold.

The swap is the part that matters for holders. Funding an acquisition of this size out of newly issued stock removes the financing risk that a bridge facility carries, and it does so by diluting existing shareholders rather than levering the balance sheet. Rocket Lab is using it to move from being primarily a launch provider toward operating a satellite communications network, a materially different business with its own capital needs. The company named no executive in the release and offered no quote, which is unusual for a strategic milestone and keeps the announcement squarely about financing mechanics.

SentiSense data shows RKLB at $62.55, down 0.6% on the day, with a bullish 30-day sentiment reading of +0.25 that sits at odds with the soft tape. Sell-side consensus remains constructive: 19 analysts carry an average target of $109.37 against a $64.00 low and a $150.00 high, with 16 buys and no sells. What to watch from here is the regulatory review, which the release names as the only outstanding condition, and whether the newly issued shares weigh on the stock while the deal sits open until mid-2027.